Press Releases

NORTH VANCOUVER, British Columbia--(BUSINESS WIRE)-- EnviroResolutions, Inc. (ENVI.PK), a publicly traded company on the pink sheets is pleased to announce the signing of a Letter of Intent to Private Label its ENVI-Clean technology with Blue Flame Stoker Inc. (BFS) of Headingley, Manitoba. BFS is a fully integrated engineering and design manufacturer of boiler systems, material handling accessories and emissions control devices. They are deeply integrated into the agriculture business and believe that ENVI-Clean products will provide state of the art solutions for their existing clients and bring them into new industries where sulphur removal and odor control are required.

"Having a reputable company like Blue Flame private label our product, shows that emissions regulations are being taken seriously by both industry and the companies that provide them with solutions," reported Geoffrey Pershick, EnviroResolutions' Sales Director. He added, "we are excited to work with BFS, as their client base reaches from the Atlantic to the Pacific".

"Whenever there is a request to private label by a reputable company like BFS, it is considered to be a massive compliment," stated Ken McClelland, EnviroResolutions Inc. President and CEO. He also mentioned "the agriculture industry holds a variety of issues we are able to address and believe our ENVI-Clean technology will integrate perfectly with the environmental issues of which BFS specializes."

EnviroResolutions Inc. has the exclusive worldwide rights to design, manufacture and market patented emission reduction technologies. The Company is currently focused on sales of its scrubbing technology to biomass and sulphur emission applications.

Notice Regarding Forward-Looking Statements

This news release contains "forward-looking statements," as that term is defined in Section 27A of the Act and Section 21E of the Securities Exchange Act of 1934. Statements in this press release, which are not purely historical, are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, the expectation and/or claim, as applicable, "...believe that ENVI-Clean products will provide state of the art solutions for their existing clients and bring them into new industries...", "the agriculture industry holds a variety of issues we are able to address and believe our ENVI-Clean technology will integrate perfectly with the environmental issues of which BFS specializes."

Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, (1) the inherent uncertainties associated with the development of an early stage company in the emissions control industry and its products and the entry into new markets for such products; (2) the risk that ENVI does not execute its business plan; (3) ENVI not being able to retain key employees; (4) markets for ENVI's products not developing as expected; and (5) ENVI's inability to finance its operations or growth. These forward-looking statements are made as of the date of this news release, and EnviroResolutions assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although EnviroResolutions believes that the beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance those beliefs, plans, expectations or intentions will prove to be accurate. Investors should consider all of the information set forth herein.

    Source: EnviroResolutions, Inc.

BEIJING, Dec. 4 /PRNewswire-Asia-FirstCall/ -- Xinhua Sports & Entertainment Limited (Nasdaq: XSEL; "XSEL"), a leading sports and entertainment media company in China, announced today that it has entered into an agreement to acquire China Sports Media ("CSM"), China's leading sports media rights distributor. CSM has popular domestic, Asia, and other content including the China Basketball Association (CBA), China Soccer League (CSL), AFC Champions League, Soccer's World Cup Qualifiers, AFC Asian Cup, Mission Hills Golf World Cup, FIFA Club World Cup, FIVB Volleyball World Championships and others.

CSM has over 80% of the Chinese sports television rights and distribution market, and is the long term partner of the All-China Sports Federation for its television rights business. CSM was also the working partner of the Chinese Olympic Committee.

Ms. Fredy Bush, XSEL's CEO commented, "CSM's current portfolio of popular domestic and Asia sports content combined with XSEL's wide range of international content makes us the leading sports rights owner in China. Furthermore, XSEL has a broad distribution platform that CSM will be able to utilize for its sports content."

Mr. Li Yi Dong, CEO of CSM said: "We are excited to be joining the XSEL family and look forward to working with our new colleagues to continue to grow the Company's leading position in China's burgeoning sports media market."

Under the terms of the transaction, CSM is valued at US$15.5 million, of which US$10.5 million will be paid in the form of approximately 5.7 million American depositary shares, (or "ADS") valued at US$1.83 per ADS and US$5 million in cash. Management believes that CSM may generate average annual net income of US$3.3 million for the period from 2010 to 2012.

Mr. LC Chang, a shareholder and director of CSM, will be appointed to the senior management of XSEL with the title of President, reporting to Fredy Bush, CEO, and will be appointed as a new director. Previously, Mr. Chang served as Executive Vice-President and Chief Marketing Officer of Sina.com responsible for its global operations, brand integration, marketing and online media sales. Prior to that, Mr. Chang was General Manager of Grey Advertising Taiwan from 1992 to 2000.

Ms. Bush added, "We welcome Mr. LC Chang to our senior management as President and also as a board member. We look forward to his valuable insights and contributions to XSEL's vision to become the leading sports media company in China."

Transaction Details

At the closing of the transaction, XSEL will issue an initial tranche of approximately eight million common shares (equivalent to 4,000,000 American depositary shares, or "ADS"), valued at US$0.915 per share (equivalent to US$1.83 per ADS), and pay US$1 million in cash to CSM's selling shareholder, with a further US$4 million in cash and approximately 3.4 million common shares to be delivered if CSM achieves certain net income and cash flow targets for 2010 and 2011.

About XSEL

Xinhua Sports & Entertainment Limited ("XSEL"; NASDAQ: XSEL) is a leading sports and entertainment media company in China. Catering to a vast audience of young and upwardly mobile consumers, XSEL is well-positioned in China with its unique content and access. Through its key international partnerships, XSEL is able to offer its target audience the content they demand -premium sports and quality entertainment. Through its Chinese partnerships, XSEL is able to deliver this content across a broad range of platforms, including television, the Internet, mobile phones and other multimedia assets in China. Along with its integrated advertising resources, XSEL offers a total solution empowering clients at every stage of the media process linking advertisers with China's young and upwardly mobile demographic.

Headquartered in Beijing, the company employs more than 1,000 people and has offices and affiliates in major cities throughout China including Beijing, Shanghai, Guangzhou, Shenzhen and Hong Kong. Xinhua Sports & Entertainment Limited shares are listed on the NASDAQ Global Market (NASDAQ: XSEL). For more information, please visit http://www.xsel.com .

Safe Harbor Statement

This announcement contains forward-looking statements. These statements are made under the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as "will," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates," "confident" and similar statements. Among other things, any quotations from management in this announcement contain forward-looking statements. Statements that are not historical facts, including statements about XSEL's beliefs and expectations are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties that could cause actual results to differ materially from those contained in any forward-looking statements. Potential risks and uncertainties include, but are not limited to, risks outlined in XSEL's filings with the U.S. Securities and Exchange Commission, including its annual report on Form 20-F. All information provided in this press release is as of the date hereof, and XSEL undertakes no duty to update such information, except as required under applicable law.

    For more information, please contact:

    Media Contact
     Joy Tsang
     XSEL
     Phone: +86-10-8567-6050; +86-136-2179-1577
     Email: joy.tsang@xsel.com

    IR Contact
     Edward Liu
     XSEL
     Phone: +86-10-8567-6061
     Email: edward.liu@xsel.com

     Howard Gostfrand
     American Capital Ventures
     Phone: +1-305-918-7000; toll free +1-877-918-0774
     Email: info@amcapventures.com

SOURCE Xinhua Sports & Entertainment Limited

SUGAR LAND, TX -- (MARKET WIRE) -- 12/04/09 -- Researched by Industrial Info Resources (Sugar Land, Texas) -- Consumers Co-operative Refineries Limited (CCRL) (Regina, Saskatchewan) is not letting current market conditions deter it from moving forward with construction of the $1.9 billion expansion project currently under way at its Regina refinery. The project consists of several new unit additions and major revamps to existing units. Construction on the new units began in the summer of 2009, and revamp modifications are expected to begin in the spring of 2010. The entire project will be complete in 2012 and will increase the total output of Saskatchewan's only oil refinery from 100,000 barrels per day (BBL/d) to 130,000 BBL/d.

For details, view the entire article by subscribing to Industrial Info's Premium Industry News at http://www.industrialinfo.com/showNews.jsp?newsitemID=153233, or browse other breaking industrial news stories at www.industrialinfo.com.

Industrial Info Resources (IIR) is the leading provider of global market intelligence specializing in the industrial process, heavy manufacturing and energy related markets. For more than 26 years, Industrial Info has provided plant and project opportunity databases, market forecasts, high resolution maps, and daily industry news. For more information, send inquiries to refininggroup@industrialinfo.com or visit us online at www.industrialinfo.com.

Add to Digg Bookmark with del.icio.us Add to Newsvine

Contact:
Joe Govreau
713-783-5147

BEIJING, Dec. 4 /PRNewswire-Asia/ -- Huaneng Power International, Inc. (NYSE: HNP; HKEx: 902; SSE: 600011) (hereinafter as "HPI" or the "Company") announced that an ultra-supercritical coal-fired generating unit (unit 2) with a capacity of 1,036MW of the Phase I Project at Huaneng Haimen Power Plant, which is wholly-owned by the Company, has recently obtained approvals from the relevant authorities and commenced commercial operation in October 2009. To date, the Company's total generation capacity on an equity basis has increased from 40,975 MW to 42,011 MW.

Huaneng Power International, Inc. wholly-owns 18 operating power plants, and has controlling interests in 16 operating power plants and minority interests in 5 operating power companies within China. Such power plants are located in 12 provinces and 4 provincial-level municipalities in China. The Company also has a wholly-owned generation company in Singapore. Currently, the Company is one of China's largest listed power producers with controlled generation capacity of 44,818MW and equity-based generation capacity of 42,011 MW.

    For enquiries, please contact:

     Huaneng Power International, Inc.
     Ms. MENG Jing / Ms. ZHAO Lin
     Tel:   +86-10-6649-1856 / 1866
     Fax:   +86-10-6649-1860
     Email: zqb@hpi.com.cn

     Wonderful Sky Financial Group Limited
     Ms. Katy CHAN / Mr. Ivan KAU / Ms. Gigi CHAN
     Tel:   +852-2851-1038
     Fax:   +852-2815-1352
     Email: katychan@wsfg.hk / ivankau@wsfg.hk / gigichan@wsfg.hk

SOURCE Huaneng Power International, Inc.

DUBLIN--(BUSINESS WIRE)-- Research and Markets (http://www.researchandmarkets.com/research/fdc39f/germany_pharmaceut) has announced the addition of the "Germany Pharmaceuticals and Healthcare Report Q1 2010" report to their offering.

Business Monitor International's Germany Pharmaceuticals and Healthcare Report provides industry professionals and strategists, corporate analysts, pharmaceutical associations, government departments and regulatory bodies with independent forecasts and competitive intelligence on Germany's pharmaceuticals and healthcare industry.

In BMI's Business Environment Ratings (BER) for Q110, Germany rose to pole position, among the nine Western European markets surveyed, having previously been ranked second behind Switzerland. The ratings criteria serve to reinforce the publisher's estimation of the country's potential owing to its strong emphasis on the regulatory environment, despite a major focus on cost-containment and industry-wide dissatisfaction over pricing and reimbursement practices. BMI calculated that Germany's pharmaceutical expenditure was EUR37.4bn (US$55.0bn) in 2008, with the sales of medicines at consumer prices forecast to rise by a compound annual growth rate (CAGR) of only 2.18% in local currency terms to 2014. In 2009 the market value is expected to increase marginally, to reach EUR38.2bn (US$53.7bn), driven by demand rather than pricing considerations. In fact, continued downward pressure on prices can be expected according to the country's industry associations.

Nevertheless, according to a study published in September 2009 by the Institute of Pharmacology at the University of Heidelberg in Germany, patients in Germany pay significantly more for their medicines than those in other European countries. The study attributes the high cost of medicines to the lack of effective price controls, claiming that the mechanisms for authorities and statutory insurance companies to reduce drug prices do not apply when a novel drug is brought into the market. Previous studies have highlighted the imposition of value-added tax (VAT) on pharmaceuticals - in comparison to the VATexempt status of medicines in most other European countries - and prescription volumes as key drivers of increased pharmaceutical spending in the country.

In the light of a difficult economic situation, after a disastrous 2009, the publisher forecasts economic expansion of just 0.9% in 2010, German authorities have continued to implement a variety of cost-containment measures. In September 2009, Germany's healthcare cost-effectiveness regulator IQWIG recommended that health insurers in the country stop reimbursing memantine, an Alzheimer's disease drug, claiming that the drug fails to provide any benefit to patients or caregivers. Since the start of the year, after recommendations by the Federal Joint Committee (G-BA), second opinions by physicians for reimbursable prescriptions of high-cost treatments for pulmonary arterial hypertension (PAH) have been mandatory. BMI believes that, despite only initially being applicable to a small patient group, introducing second opinions to prescriptions will introduce an unnecessary level of bureaucracy to the system, therefore slowing patients' access to essential medicines.

Despite the challenges, the German pharmaceutical marketplace remains a dynamic one. For example, in August 2009, local biopharmaceutical company Apogenix received EUR2.6mn (US$3.6mn) from the federal government to help the company to develop chronic inflammatory disease and oncology candidates. The grant is part of a EUR40mn (US$56.3mn) scheme for businesses in Germany's Rhine- Neckar biotech cluster. In the same month, Belgian pharmaceutical group UCB and Swiss drugmaker Novartis signed a licensing deal for cardiovascular and diabetes products in order to expand in Germany.

Key Topics Covered:

    --  Executive Summary
    --  SWOT Analysis
    --  Pharmaceutical Business Environment Ratings
    --  Germany - Market Summary
    --  Prescription Market Forecast
    --  Competitive Landscape
    --  Company Profiles
    --  Country Snapshot: Germany Demographic Data
    --  BMI Methodology

Companies Mentioned:

    --  GlaxoSmithKline (GSK)
    --  Pfizer
    --  Novartis
    --  Sanofi-Aventis
    --  Merck & Co
    --  Bayer Schering
    --  Boehringer Ingelheim
    --  Stada Arzneimittel

For more information visit http://www.researchandmarkets.com/research/fdc39f/germany_pharmaceut

    Source: Research and Markets